Brief: Palatin Technologies Says Melody-1 Phase 3 Clinical Study Continuing Patient Enrollment
27/04/2023 14:07
April 27 (Reuters) - Palatin Technologies Inc PTN.A :
* PALATIN TECHNOLOGIES INC - MELODY-1 PHASE 3 CLINICAL
STUDY
CONTINUING PATIENT ENROLLMENT - FINAL DATA SECOND HALF OF 2023
Source text for Eikon: ID:
Further company coverage: PTN.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Palatin Technologies
See all newsPalatin Technologies Inc reports results for the quarter ended March 31 - Earnings Summary
Palatin Technologies Inc expected to post a loss of $1.20 a share - Earnings Preview
Palatin Technologies Q2 revenue rises yr/yr, net loss widens
Brief: Palatin Announces 1-For-50 Reverse Stock Split
Brief: Palatin Announces Positive Preclinical Efficacy Data For Oral MC4R Agonist PL7737 In Animal Model Of Obesity